Brenipatide for Alcohol use disorder

Phase 3ActiveEli Lilly and Company (LLY)

Indications for Brenipatide: Alcohol use disorder · Phase 3 Tobacco use disorder · Phase 2 Opioid use disorder · Phase 2 Schizophrenia · Phase 2 Bipolar disorder · Phase 2 Major depressive disorder · Phase 3

Two 56-week Phase 3 placebo-controlled trials (RENEW-ALC-1/-2, ~1,100 each, 8 countries) of brenipatide in AUD with change in drinking patterns (TLFB) as primary endpoint. Lilly advanced directly from Phase 1 to Phase 3 in AUD.

Data current as of 1 Apr 2028

Development timeline

Phase 3Oct 2025 – Apr 2028

Apr 2028
Upcoming↗
Apr 2028
Upcoming↗
Sept 2026
Conference presentationConference Presentation↗
Aug 2026
Trial startedTrial Started
Feb 2026
Trial startedTrial Started
Feb 2026
Trial startedTrial Started
Feb 2026
Trial startedTrial Started
Nov 2025
Trial startedTrial Started
Nov 2025
Trial startedTrial Started
Oct 2025
Trial startedTrial Started
Oct 2025
Programme became clinically active with first patient-trial start in this indication; all trials recruiting as of Oct 2026.
Oct 2025
Trial startedTrial Started

Readouts

Primary completion Apr 2028 (RENEW-ALC-1)AnticipatedTopline dataNCT07219966
Primary completion Apr 2028 (RENEW-ALC-2)AnticipatedTopline dataNCT07219953

Clinical trials in Alcohol use disorder

NCT07219953J2S-MC-GZMPPhase 3Recruitingn=1100

A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2)

Started Oct 2025· Primary completion Apr 2028· 📍 117 sites across 8 countries (United States, China, Japan, South Korea)

mixed

NCT07219966J2S-MC-GZMEPhase 3Recruitingn=1100

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

Started Oct 2025· Primary completion Apr 2028· 📍 121 sites across 8 countries (United States, China, Japan, South Korea)

mixed

Formulations

Formulation	Route	Regimen	Pharmacokinetics
Brenipatide subcutaneous	Subcutaneous	—	—

Mechanism of action (compound-wide)

Dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR).

Target	Action	Affinity
Glucagon-like peptide 1 receptorprimaryGLP1R	Agonist	—ⓘ
Gastric inhibitory polypeptide receptorGIPR	Agonist	—ⓘ

← Full Brenipatide compound page (identity, identifiers, all indications)

Sources

ClinicalTrials.gov NCT07219953: A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2) — ClinicalTrials.gov
ClinicalTrials.gov NCT07219966: A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07223840: A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07286175: A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07410507: A Study of Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07412756: A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07420283: A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1) — ClinicalTrials.gov
ClinicalTrials.gov NCT07775300: A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder (RENEW-MDD-2) — ClinicalTrials.gov
Eli Lilly Q2 2026 earnings presentation (pipeline as of Aug 3, 2026; brenipatide trial table sourced from CT.gov Jul 30, 2026) — Company press release
GEN: Lilly's GIP/GLP-1 candidate brenipatide shows early clinical promise (Psych Congress 2026 posters) — News